Study of ACE1831 for patients with IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests an investigational drug, ACE1831, in people with active IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and swelling in organs. The purpose is to see if ACE1831 is safe and effective in reducing disease flare-ups, possibly offering a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with IgG4-related disease that currently affects at least two organs, with at least one organ (not including lymph nodes) having an active flare needing treatment.
- Your blood test shows a higher than normal level of IgG4 protein.
- You are able to take steroids (like prednisone) for the current flare and can stop them by day 5 of the study.
- You agree to use contraception for a certain period after the study treatment.
- You do not have other serious medical conditions, infections, or a history of cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial is testing a new investigational drug called IMM0306 for people with IgG4-related disease, a condition where the body's immune system attacks its own organs. If you're currently needing steroids for a flare, this study might offer a new treatment option that could help control the disease with fewer side effects.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
This trial tests a combination of an herbal medicine (Tripterygium wilfordii) and the steroid prednisone to see if it helps control symptoms of IgG4-related disease, a condition where the immune system attacks your own organs. The study aims to find a more effective or safer treatment option.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.